Profile data is unavailable for this security.
About the company
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
- Revenue in USD (TTM)182.33k
- Net income in USD-108.09m
- Incorporated2001
- Employees134.00
- LocationInovio Pharmaceuticals Inc660 W. Germantown Pike, Suite 110PLYMOUTH MEETING 19462United StatesUSA
- Phone+1 (858) 410-3134
- Fax+1 (858) 404-1392
- Websitehttps://www.inovio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turn Therapeutics Inc | -100.00bn | -100.00bn | 107.77m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Korro Bio Inc | 7.37m | -88.42m | 108.30m | 87.00 | -- | 1.09 | -- | 14.69 | -9.42 | -9.42 | 0.7855 | 10.54 | 0.0364 | -- | 1.36 | 70,875.00 | -43.65 | -- | -46.92 | -- | -- | -- | -1,199.53 | -- | -- | -- | 0.00 | -- | -- | -- | -2.97 | -- | -- | -- |
| Oncolytics Biotech Inc | 0.00 | -25.79m | 109.76m | 29.00 | -- | 1,257.10 | -- | -- | -0.2868 | -0.2868 | 0.00 | 0.0008 | 0.00 | -- | -- | -- | -179.40 | -75.50 | -293.88 | -87.03 | -- | -- | -- | -- | -- | -- | 0.879 | -- | -- | -- | -14.26 | -- | 85.40 | -- |
| Cassava Sciences Inc | 0.00 | -106.03m | 112.07m | 30.00 | -- | 1.37 | -- | -- | -2.20 | -2.20 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -59.99 | -28.22 | -85.37 | -29.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 74.96 | -- | 41.75 | -- |
| ALX Oncology Holdings Inc | 0.00 | -108.01m | 114.94m | 44.00 | -- | 2.54 | -- | -- | -2.01 | -2.01 | 0.00 | 0.8362 | 0.00 | -- | -- | 0.00 | -80.47 | -37.96 | -103.67 | -40.71 | -- | -- | -- | -46,390.86 | -- | -- | 0.2099 | -- | -- | -- | 16.14 | -- | 4.84 | -- |
| Coya Therapeutics Inc | 3.99m | -18.43m | 115.13m | 8.00 | -- | 3.01 | -- | 28.87 | -1.11 | -1.11 | 0.2397 | 1.63 | 0.118 | -- | -- | 498,462.50 | -54.54 | -- | -59.84 | -- | -- | -- | -462.26 | -- | -- | -- | 0.00 | -- | -40.79 | -- | -86.29 | -- | -- | -- |
| Equillium Inc | 4.39m | -24.42m | 116.92m | 35.00 | -- | 3.77 | -- | 26.62 | -0.632 | -0.632 | 0.1021 | 0.5099 | 0.1274 | -- | 1.71 | 125,485.70 | -70.81 | -44.86 | -89.09 | -58.85 | -- | -- | -555.94 | -164.30 | -- | -- | 0.00 | -- | 13.89 | -- | 39.51 | -- | 2.81 | -- |
| Aardvark Therapeutics Inc | 0.00 | -48.77m | 119.10m | 33.00 | -- | 0.972 | -- | -- | -2.53 | -2.53 | 0.00 | 5.63 | 0.00 | -- | -- | -- | -44.96 | -- | -47.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -185.63 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 182.33k | -108.09m | 119.54m | 134.00 | -- | -- | -- | 655.65 | -2.63 | -2.63 | 0.0046 | -0.1441 | 0.0021 | -- | 0.1283 | 1,360.67 | -122.52 | -58.57 | -260.08 | -70.33 | -- | -- | -59,283.97 | -4,810.90 | -- | -6.49 | -- | -- | -73.83 | -44.44 | 20.62 | -- | -13.16 | -- |
| Agenus Inc | 106.83m | -35.38m | 120.71m | 316.00 | -- | -- | -- | 1.13 | -2.09 | -2.09 | 3.94 | -8.35 | 0.4523 | -- | 286.79 | 338,066.50 | -16.63 | -58.29 | -- | -140.29 | 98.93 | 97.31 | -36.77 | -125.67 | -- | -1.17 | 6.78 | -- | -33.81 | -7.17 | 7.54 | -- | -34.16 | -- |
| Tenaya Therapeutics Inc | 0.00 | -94.26m | 121.83m | 97.00 | -- | 1.13 | -- | -- | -0.7875 | -0.7875 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -76.77 | -47.44 | -87.21 | -51.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.44 | -- | -18.92 | -- |
| MacroGenics Inc | 127.63m | -75.89m | 122.72m | 341.00 | -- | 1.83 | -- | 0.9616 | -1.21 | -1.21 | 2.02 | 1.06 | 0.4769 | 5.23 | 3.27 | 374,266.90 | -28.36 | -33.40 | -35.18 | -40.60 | 75.41 | -- | -59.46 | -97.17 | 5.02 | -26.97 | 0.5119 | -- | 155.26 | 18.50 | -639.30 | -- | -2.88 | -- |
| Spero Therapeutics Inc | 40.55m | -43.84m | 123.38m | 32.00 | -- | 4.65 | -- | 3.04 | -0.7949 | -0.7949 | 0.7299 | 0.4705 | 0.4283 | -- | 1.45 | 1,267,156.00 | -46.31 | -35.16 | -69.26 | -42.63 | -- | -- | -108.11 | -111.75 | -- | -- | 0.00 | -- | -53.77 | 21.46 | -400.65 | -- | -- | -- |
| Genelux Corp | 0.00 | -31.87m | 130.56m | 24.00 | -- | 5.91 | -- | -- | -0.8803 | -0.8803 | 0.00 | 0.4943 | 0.00 | -- | -- | 0.00 | -97.69 | -125.27 | -116.81 | -- | -- | -- | -- | -830.46 | -- | -- | 0.00 | -- | -95.29 | -- | -5.56 | -- | -26.46 | -- |
| Cardiff Oncology Inc | 593.00k | -45.88m | 132.63m | 31.00 | -- | 2.92 | -- | 223.66 | -0.6873 | -0.6873 | 0.0089 | 0.6645 | 0.0075 | -- | 1.24 | 19,129.03 | -57.65 | -36.79 | -70.95 | -40.48 | -- | -- | -7,732.04 | -7,960.06 | -- | -- | 0.00 | -- | -13.18 | 10.13 | -0.9262 | -- | -26.97 | -- |
| Oramed Pharmaceuticals, Inc. | 2.00m | 43.85m | 132.94m | 13.00 | 3.32 | 0.671 | 3.03 | 66.47 | 1.01 | 1.01 | 0.0478 | 4.98 | 0.0104 | -- | -- | 153,846.20 | 22.72 | -- | 23.30 | -- | 0.65 | -- | 2,190.40 | -- | -- | -- | 0.00 | -- | -100.00 | -- | -444.98 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Inovio Pharmaceuticals Inc's reporting currency: US Dollar USD
40.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 9.85m | 14.33% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 3.31m | 4.82% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.89m | 4.21% |
| Adage Capital Management LPas of 31 Dec 2025 | 2.55m | 3.72% |
| Boxer Capital Management LLCas of 31 Dec 2025 | 2.42m | 3.52% |
| D. E. Shaw & Co. LPas of 31 Dec 2025 | 2.23m | 3.25% |
| Adar1 Capital Management LLCas of 31 Dec 2025 | 1.49m | 2.16% |
| Millennium Management LLCas of 31 Dec 2025 | 1.40m | 2.04% |
| Geode Capital Management LLCas of 31 Dec 2025 | 769.36k | 1.12% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 608.24k | 0.89% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
